Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 S095029 + pembrolizumab in advanced MSI-H/dMMR gastric or gastroesophageal junction cancer
jRCT2031240729Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of sym021 and pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and Nonhematologic neoplasms, sponsored by Servier. Primary endpoints: Number of Dose-Limiting Toxicities (DLTs), Total Number of Adverse Events (AEs) and 3 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
sym021pembrolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240729.